Literature DB >> 24127110

[Vaccination in the elderly].

A Kwetkat1, M W Pletz.   

Abstract

The aging immune system, so-called immunosenescence, is well documented as the cause of increased infection rates and severe, often complicated course of infections in the elderly with increased morbidity and mortality rates. Furthermore, it can lead to decreased efficacy of vaccination. The administration of more immunogenic vaccines can be beneficial in the elderly. Implementing vaccination recommendations for the elderly by STIKO can reduce burden of infectious diseases by prevention of infection or reduction of severity of infection. The following vaccinations are recommended by STIKO for all persons aged 60 and above: annual influenza vaccination (additionally all nursing home residents independently of age), once only pneumococcal polysaccharide vaccination, completion of tetanus and diphtheria (Td) vaccination as well as regular revaccination. All adults should be vaccinated against pertussis with Tdap vaccine once. Meanwhile, pneumococcal conjugate vaccine is allowed for administration in adults but is not recommended by STIKO yet. A lifelong course of vaccination may help to attenuate the effect of immunosenescence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24127110     DOI: 10.1007/s00391-013-0532-6

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  24 in total

1.  Effect of influenza on functional decline.

Authors:  Pedro L Gozalo; Aurora Pop-Vicas; Zhanlian Feng; Stefan Gravenstein; Vincent Mor
Journal:  J Am Geriatr Soc       Date:  2012-06-21       Impact factor: 5.562

Review 2.  Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis.

Authors:  W E P Beyer; J J P Nauta; A M Palache; K M Giezeman; A D M E Osterhaus
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

3.  Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults.

Authors:  Xu Yao; Robert G Hamilton; Nan-ping Weng; Qian-Li Xue; Jay H Bream; Huifen Li; Jing Tian; Shu-Hui Yeh; Barbara Resnick; Xiyan Xu; Jeremy Walston; Linda P Fried; Sean X Leng
Journal:  Vaccine       Date:  2011-05-10       Impact factor: 3.641

4.  Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.

Authors:  Wayde M Weston; Leonard R Friedland; Xiangfeng Wu; Barbara Howe
Journal:  Vaccine       Date:  2011-12-31       Impact factor: 3.641

5.  Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study.

Authors:  Santiago Ewig; Benjamin Klapdor; Mathias W Pletz; Gernot Rohde; Hartwig Schütte; Tom Schaberg; Torsten T Bauer; Tobias Welte
Journal:  Thorax       Date:  2011-11-05       Impact factor: 9.139

6.  Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

Authors:  M A Julie Westerink; Harry W Schroeder; Moon H Nahm
Journal:  Aging Dis       Date:  2011-07-20       Impact factor: 6.745

Review 7.  Streptococcus pneumoniae vaccination in older adults.

Authors:  Elizabeth Rightmier; Vanessa Stevens; Jack Brown
Journal:  Am J Geriatr Pharmacother       Date:  2011-11-02

8.  [Immunisation coverage in the adult workforce 2003. Utilisation of routine occupational health checks to ascertain vaccination coverage in employees].

Authors:  H-M Bader; P Egler
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2004-12       Impact factor: 1.513

9.  [Influenza and pneumococcal vaccination in adults].

Authors:  T Weinke; W Güthoff
Journal:  Dtsch Med Wochenschr       Date:  2009-04-07       Impact factor: 0.628

10.  Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly.

Authors:  A Domínguez; C Izquierdo; L Salleras; L Ruiz; D Sousa; J-M Bayas; M Nebot; W Varona; J-M Celorrio; J Carratalà
Journal:  Eur Respir J       Date:  2010-01-14       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.